Gowans J D
Curr Med Res Opin. 1981;7(6):384-91.
Sodium meclofenamate (200 to 400 mg daily) was compared with aspirin (2.4 to 4.8 g daily) for the treatment of rheumatoid arthritis in a 6-month, double-blind, multicentre study. Two groups of patients participated, one receiving stabilized doses of concomitant gold or steroid therapy and one not receiving such therapy. In these latter patients, sodium meclofenamate appeared to be more effective than aspirin; tenderness was reduced from 35% to 50% more on sodium meclofenamate throughout the study, the differences being statistically significant during the first 2 months, and over all condition improved in a significantly greater proportion of the patients receiving sodium meclofenamate. Among the patients receiving concomitant gold or steroid, neither drug appeared to be as effective as in the group not receiving the concomitant therapy and the results with both aspirin and sodium meclofenamate were virtually the same for all measures. With sodium meclofenamate the most common adverse reaction was diarrhoea; and with aspirin, it was tinnitus. The incidence of withdrawals for adverse reactions did not differ significantly between the two medication groups. Abnormal laboratory values were observed in a few patients, but the incidence did not differ between the groups. On the basis of the study, sodium meclofenamate appears to be relatively well tolerated and at least as effective as aspirin in the treatment of the symptoms of rheumatoid arthritis.
在一项为期6个月的双盲多中心研究中，对甲氯芬那酸钠（每日200至400毫克）和阿司匹林（每日2.4至4.8克）治疗类风湿性关节炎的效果进行了比较。两组患者参与了研究，一组接受稳定剂量的金制剂或类固醇联合治疗，另一组未接受此类治疗。在未接受联合治疗的患者中，甲氯芬那酸钠似乎比阿司匹林更有效；在整个研究过程中，服用甲氯芬那酸钠的患者压痛减轻幅度比服用阿司匹林的患者多35%至50%，在前两个月差异具有统计学意义，并且接受甲氯芬那酸钠治疗的患者整体病情改善的比例明显更高。在接受金制剂或类固醇联合治疗的患者中，两种药物似乎都不如未接受联合治疗组有效，阿司匹林和甲氯芬那酸钠在所有指标上的结果几乎相同。服用甲氯芬那酸钠最常见的不良反应是腹泻；服用阿司匹林则是耳鸣。两个药物治疗组因不良反应而退出研究的发生率没有显著差异。少数患者出现了实验室检查值异常，但两组之间的发生率没有差异。基于该研究，甲氯芬那酸钠在治疗类风湿性关节炎症状方面似乎耐受性相对良好，且至少与阿司匹林效果相当。
